Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report

BACKGROUND: Nivolumab is a monoclonal antibody against programmed death 1 and has become a standard treatment of advanced melanoma because of its durable response and survival benefits. In this report, we present a case of severe intestinal perforation after nivolumab immunotherapy for malignant mel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuda, Koji, Tanaka, Toshiaki, Ishihara, Soichiro, Otani, Kensuke, Nishikawa, Takeshi, Kiyomatsu, Tomomichi, Kawai, Kazushige, Hata, Keisuke, Nozawa, Hiroaki, Masui, Yuri, Shintani, Yukako, Watanabe, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572476/
https://www.ncbi.nlm.nih.gov/pubmed/28842844
http://dx.doi.org/10.1186/s40792-017-0370-7
Descripción
Sumario:BACKGROUND: Nivolumab is a monoclonal antibody against programmed death 1 and has become a standard treatment of advanced melanoma because of its durable response and survival benefits. In this report, we present a case of severe intestinal perforation after nivolumab immunotherapy for malignant melanoma. CASE PRESENTATION: A 73-year-old man with stage IV malignant melanoma underwent nivolumab therapy. The patient presented to our hospital because of a progressing abdominal pain. Radiological evaluation revealed evidence of free intraperitoneal air. Therefore, we diagnosed the patient as having an intestinal perforation, which was successfully resolved after surgical treatment. CONCLUSION: Although intestinal perforation after nivolumab immunotherapy is rare, it can be severe and requires early diagnosis and emergency surgery to ensure a favorable prognosis.

Ejemplares similares